SGLT2の機能とその阻害薬を用いた基礎的研究の進展

DOI Web Site Web Site

書誌事項

タイトル別名
  • The Functions of SGLT2 and the Recent Advances in the Studies of SGLT2 Inhibitors
  • SGLT2 ノ キノウ ト ソノ ソガイヤク オ モチイタ キソテキ ケンキュウ ノ シンテン

この論文をさがす

抄録

Glucose is a main energy source for ATP production and its effective utilization is important to maintain homeostasis. Although glucose is filtrated in glomerulus, sodium glucose co–transporter 1/2 (SGLT1/2) in the renal tubules reabsorbs it. SGLT2 selectively expresses in the proximal tubules and reabsorbs a large fraction of glucose, while SGLT1 exists in the kidney and small intestine to take up both glucose and galactose. Accordingly, SGLT2 inhibition could block glucose reabsorption and, indeed, SGLT2 inhibitors show the expected effects. Importantly, human SGLT2 deficiency or SGLT2 knockout mice show no remarkable phenotypes except renal glycosuria, supporting that SGLT2 inhibitors could be relatively safe. In addition, recent studies reveal that treatment with SGLT2 inhibitors improves a variety of metabolic syndromes, such as nonalcoholic steatosis, atherosclerosis and diabetic nephropathy. In this review, we introduce the characterization of SGLT2 and the effect of SGLT2 inhibitors on metabolic syndromes.

収録刊行物

  • 膜

    膜 46 (1), 38-43, 2021

    日本膜学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ